Search

Your search keyword '"Ziepert, M"' showing total 220 results
Start Over Author "Ziepert, M"
220 results on '"Ziepert, M"'

2. Allogeneic transplantation in T‐cell lymphoma: Lessons from the AATT study

Author

Tournilhac, O., primary, Altmann, B., additional, Friedrichs, B., additional, Bouabdallah, K., additional, Cartron, G., additional, Nickelsen, M., additional, Wulf, G., additional, Leclerc, M., additional, Vilatte, A., additional, Turlure, P., additional, Sanhès, L., additional, Houot, R., additional, Roussel, M., additional, de Leval, L., additional, Rosenwald, A., additional, Gaulard, P., additional, Dreger, P., additional, Glass, B., additional, Latière, C., additional, Damaj, G., additional, Lenz, G., additional, Reimer, P., additional, Banos, A., additional, Bilger, K., additional, Durot, E., additional, Sibon, D., additional, Wagner, E., additional, Nguyen, S., additional, Trümper, L., additional, Ziepert, M., additional, and Schmitz, N., additional

Published
2023
Full Text
View/download PDF

8. S101: GENETIC AND EPIGENETIC FACTORS DRIVING PRIMARY MEDIASTINAL B-CELL LYMPHOMA PATHOGENESIS AND OUTCOME

Author

Noerenberg, D., primary, Briest, F., additional, Hennch, C., additional, Yoshida, K., additional, Nimo, J., additional, Hablesreiter, R., additional, Takeuchi, Y., additional, Sasca, D., additional, Ueno, H., additional, Mansouri, L., additional, Inoue, Y., additional, Wiegand, L., additional, Staiger, A. M., additional, Casadei, B., additional, Ziepert, M., additional, Asmar, F., additional, Korkolopoulou, P., additional, Kirchner, M., additional, Mertins, P., additional, Weiner, J., additional, Toth, E., additional, Weber, T., additional, Warth, A., additional, Schneider, T., additional, Amini, R.-M., additional, Klapper, W., additional, Hummel, M., additional, Poeschel, V., additional, Kanellis, G., additional, Rosenwald, A., additional, Held, G., additional, Campo, E., additional, Stamatopoulos, K., additional, Anagnostopoulos, I., additional, Bullinger, L., additional, Goldschmidt, N., additional, Zinzani, P. L., additional, Bödor, C., additional, Rosenquist, R., additional, Vassilakopoulos, T. P., additional, Ott, G., additional, Ogawa, S., additional, and Damm, F., additional

Published
2022
Full Text
View/download PDF

13. SPARC-positive macrophages are the superior prognostic factor in the microenvironment of diffuse large B-cell lymphoma and independent of MYC rearrangement and double-/triple-hit status

Author

Croci, G.A., primary, Au-Yeung, R.K.H., additional, Reinke, S., additional, Staiger, A.M., additional, Koch, K., additional, Oschlies, I., additional, Richter, J., additional, Poeschel, V., additional, Held, G., additional, Loeffler, M., additional, Trümper, L., additional, Rosenwald, A., additional, Ott, G., additional, Spang, R., additional, Altmann, B., additional, Ziepert, M., additional, and Klapper, W., additional

Published
2021
Full Text
View/download PDF

17. Relapsed / Refractory International Prognostic Index (R/R-IPI): An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma

Author

Maurer, MJ, Jakobsen, LH, Mwangi, R, Schmitz, N, Farooq, U, Flowers, CR, de Nully Brown, P, Thompson, CA, Frederiksen, H, Cunningham, D, Jorgensen, J, Poeschel, V, Nowakowski, G, Seymour, JF, Merli, F, Haioun, C, Ghesquieres, H, Ziepert, M, Tilly, H, Salles, G, Shi, Q, El-Galaly, TC, Habermann, TM, Maurer, MJ, Jakobsen, LH, Mwangi, R, Schmitz, N, Farooq, U, Flowers, CR, de Nully Brown, P, Thompson, CA, Frederiksen, H, Cunningham, D, Jorgensen, J, Poeschel, V, Nowakowski, G, Seymour, JF, Merli, F, Haioun, C, Ghesquieres, H, Ziepert, M, Tilly, H, Salles, G, Shi, Q, El-Galaly, TC, and Habermann, TM

Abstract

Disease progression after frontline therapy for Diffuse large B-cell lymphoma (DLBCL) is a clinically significant event. Patients who experience early progression or have refractory disease have especially poor outcomes. Simple, clinically applicable prognostic tools are needed for selecting patients for consideration for novel therapies and prognostication in the relapsed/refractory (R/R) setting. Model building was performed in patients from the Surrogate endpoints in aggressive lymphoma (SEAL) consortium with disease progression after frontline immunochemotherapy. The primary endpoint was overall survival (OS) measured from date of progression. Validation was performed in the University of Iowa/Mayo Clinic SPORE Molecular Epidemiology Resource (MER) and Danish National Lymphoma Register (LYFO) cohorts. Model performance was assessed using time-dependent concordance indices (c-statistic) and calibration with metrics evaluated at 2 years from progression. Note, 1234 of 5112 patients treated with frontline immunochemotherapy in the SEAL consortium developed progressive disease. Time to progression on immunochemotherapy and age at progression were strongly associated with post-progression OS (both p < 0.001). A prognostic model was developed incorporating spline fit for both variables. The model had good concordance in the discovery (0.67) and validation sets (LYFO c = 0.64, MER c = 0.68) with generally good calibration. Time to progression on frontline therapy is strongly associated with post-progression OS in DLBCL. We developed and validated a simple to apply clinical prognostic tool in the R/R setting. The useful prediction of expected outcomes in R/R DLBCL and can inform treatment decisions such as considerations for CAR-T therapy as well as trial designs. The model is available in smartphone-based point of care applications.

Published
2021

21. Analysis of a safety run-in cohort from NIVEAU, a phase 3 study for patients with aggressive Non-Hodgkin lymphoma in first relapse or progression not eligible for High-Dose Chemotherapy (HDT) testing Nivolumab in combination with (R)-GemOx

Author

Thurner, L., Poeschel, V, Haioun, C., Houot, R., Gaulard, P., Molina, T., Rosenwald, A., Andre, M., Hoffmann, J., Dreyling, M., Casasnovas, O., Maisonneuve, H., Tilly, H., Illmer, T., Mayer, S., Kirchen, H., La Rosee, P., Loeffler, M., Ziepert, M., Altmann, B, Held, G., Jonchère, Laurent, Saarland University [Saarbrücken], CHI Créteil, Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Julius-Maximilians-Universität Würzburg (JMU), CHU UCL Namur, Philipps Universität Marburg = Philipps University of Marburg, University-Hospital Munich-Großhadern [München], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon (CHD Vendée), Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Universität Regensburg (UR), Universität Leipzig, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Julius-Maximilians-Universität Würzburg [Wurtzbourg, Allemagne] (JMU), Philipps Universität Marburg, Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon, and Universität Leipzig [Leipzig]

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2020

23. Role of radiotherapy and dose-densification of R-CHOP in primary mediastinal B-cell lymphoma: a subgroup analysis of the unfolder trial of the German Lymphoma Alliance (GLA)

Author

Thurner, L., Held, G., Poeschel, V, Berdel, C., Ott, G., Schmidt, C., Viardot, A., Engel-Riedel, W., Borchmann, P., Shpilberg, O., Witzens-Harig, M., Frickhofen, N., Nickelsen, M., Griesinger, F., Krammer-Steiner, B., Neubauer, A., Federico, M., Brown, de Nully P., Stilgenbauer, S., Murawski, N., Altmann, B., Truemper, L., Schmidberger, H., Ruebe, C., Fleckenstein, J., Schmitz, N., Loeffler, M., Ziepert, M., Thurner, L., Held, G., Poeschel, V, Berdel, C., Ott, G., Schmidt, C., Viardot, A., Engel-Riedel, W., Borchmann, P., Shpilberg, O., Witzens-Harig, M., Frickhofen, N., Nickelsen, M., Griesinger, F., Krammer-Steiner, B., Neubauer, A., Federico, M., Brown, de Nully P., Stilgenbauer, S., Murawski, N., Altmann, B., Truemper, L., Schmidberger, H., Ruebe, C., Fleckenstein, J., Schmitz, N., Loeffler, M., and Ziepert, M.

Published
2020

24. 10-year follow-up of the R-MegaCHOEP trial: conditional survival analysis reveals 1-year progression-free survival as crucial prognostic factor for long-term outcome in young high-risk patients with aggressive B-cell lymphoma

Author

Frontzek, F., Ziepert, M., Nickelsen, M., Altmann, B., Glass, B., Haenel, M., Truemper, L., Held, G., Bentz, M., Borchmann, P., Dreyling, M., Viardot, A., Kroschinsky, F., Metzner, B., Staiger, A. M., Horn, H., Ott, G., Rosenwald, A., Loeffler, M., Lenz, G., Schmitz, N., Frontzek, F., Ziepert, M., Nickelsen, M., Altmann, B., Glass, B., Haenel, M., Truemper, L., Held, G., Bentz, M., Borchmann, P., Dreyling, M., Viardot, A., Kroschinsky, F., Metzner, B., Staiger, A. M., Horn, H., Ott, G., Rosenwald, A., Loeffler, M., Lenz, G., and Schmitz, N.

Published
2020

30. FIRST-LINE THERAPY OF T-CELL LYMPHOMA: ALLOGENEIC OR AUTOLOGOUS TRANSPLANTATION FOR CONSOLIDATION - FINAL RESULTS OF THE AATT STUDY

Author

Tournilhac, O., primary, Truemper, L., additional, Ziepert, M., additional, Bouabdallah, K., additional, Nickelsen, M., additional, Maury, S., additional, Reimer, P., additional, Jaccard, A., additional, Herr, W., additional, Wilhelm, M., additional, Cartron, G., additional, Wulf, G., additional, Sanhes, L., additional, Dreger, P., additional, Lamy, T., additional, Kroschinsky, F., additional, Lindemann, H., additional, Roussel, M., additional, Viardot, A., additional, Sibon, D., additional, Delmer, A., additional, De Leval, L., additional, Damaj, G.L., additional, Gisselbrecht, C., additional, Gaulard, P., additional, Rosenwald, A., additional, Friedrichs, B., additional, Altmann, B., additional, and Schmitz, N., additional

Published
2019
Full Text
View/download PDF

32. THE CLINICAL COURSE OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) OVER TIME: A MULTISTATE SURVIVAL ANALYSIS USING META-DATA FROM 13 FIRST-LINE RANDOMIZED TRIALS

Author

Çağlayan, Ç., primary, Dixon, J.G., additional, Salles, G., additional, Wall, A., additional, Schmitz, N., additional, Cunningham, D., additional, Poeschel, V., additional, Seymour, J., additional, Jaeger, U., additional, Habermann, T., additional, Merli, F., additional, Haioun, C., additional, Tilly, H., additional, Ghesiquieres, H., additional, Ziepert, M., additional, Flament, J., additional, Shi, Q., additional, and Flowers, C., additional

Published
2019
Full Text
View/download PDF

33. COMPARISON OF CLINICAL SCORING SYSTEMS IN AGGRESSIVE B-CELL LYMPHOMAS (BCL): AN INDIVIDUAL PATIENT-LEVEL ANALYSIS ACROSS INTERNATIONAL TRIAL

Author

Schmitz, N.F., primary, Dixon, J.G., additional, Salles, G., additional, Wall, A., additional, Cunningham, D., additional, Poeschel, V., additional, Haioun, C., additional, Tilly, H., additional, Ghesquieres, H., additional, Ziepert, M., additional, Flament, J., additional, Flowers, C., additional, Shi, Q., additional, and Ruppert, A.S., additional

Published
2019
Full Text
View/download PDF

34. INTENSIVE IMMUNOCHEMOTHERAPY (R-CHOEP) VS HIGH-DOSE IMMUNOCHEMOTHERAPY (R-MegaCHOEP) IN YOUNG PATIENTS WITH AGGRESSIVE B-CELL LYMPHOMA: A 10-YEAR LONG-TERM FOLLOW-UP

Author

Frontzek, F., primary, Ziepert, M., additional, Nickelsen, M., additional, Altmann, B., additional, Glaß, B., additional, Hänel, M., additional, Trümper, L., additional, Held, G., additional, Bentz, M., additional, Borchmann, P., additional, Dreyling, M., additional, Viardot, A., additional, Metzner, B., additional, Kroschinsky, F., additional, Staiger, A.M., additional, Ott, G., additional, Rosenwald, A., additional, Löffler, M., additional, Lenz, G., additional, and Schmitz, N., additional

Published
2019
Full Text
View/download PDF

35. SAMD14/NEURABIN-I AS BCR-ANTIGENS OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

Author

Thurner, L., primary, Bewarder, M., additional, Fadle, N., additional, Regitz, E., additional, Poeschel, V., additional, Ziepert, M., additional, Schuck, R., additional, Altmeyer, S., additional, Kemele, M., additional, Bock, T., additional, Schormann, C., additional, Walter, S., additional, Szczepanowski, M., additional, Klapper, W., additional, Monoranu, C., additional, Rosenwald, A., additional, Moeller, P., additional, Kim, Y., additional, Buslei, R., additional, Kaddu-Mulindwa, D., additional, Neumann, F., additional, Roemer, K., additional, Bohle, R., additional, Illerhaus, G., additional, Schorb, E., additional, Schaefer, H., additional, Hansmann, M.L., additional, Hartmann, S., additional, Held, G., additional, Stilgenbauer, S., additional, Murawski, N., additional, Pfreundschuh, M., additional, and Preuss, K.D., additional

Published
2019
Full Text
View/download PDF

36. Radiotherapy (RT) to bulky (B) and extralymphatic (E) disease in combination with 6xR-CHOP-14 or R-CHOP-21 in young good-prognosis DLBCL patients: Results of the 2x2 randomized UNFOLDER trial of the DSHNHL/GLA

Author

Murawski, N., Poeschel, V., Ziepert, M., Altmann, B., Dreyling, M., Borchmann, P., Viardot, A., Luminari, S., Witzens-Harig, M., Dierlamm, J., Haenel, M., Truemper, L., Metzner, B., Lengfelder, E., Keller, U., Ruebe, C., Berdel, C., Schmitz, N., Held, G., Pfreundschuh, M., Murawski, N., Poeschel, V., Ziepert, M., Altmann, B., Dreyling, M., Borchmann, P., Viardot, A., Luminari, S., Witzens-Harig, M., Dierlamm, J., Haenel, M., Truemper, L., Metzner, B., Lengfelder, E., Keller, U., Ruebe, C., Berdel, C., Schmitz, N., Held, G., and Pfreundschuh, M.

Published
2018

37. Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP:results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial

Author

Kühnl, A., Cunningham, D., Counsell, N., Hawkes, E.A., Qian, W., Smith, P., Chadwick, N., Lawrie, A., Mouncey, P., Jack, A., Pocock, C., Ardeshna, K.M., Radford, J., McMillan, A., Davies, J., Turner, D., Kruger, A., Johnson, P., Gambell, J., Rosenwald, A., Ott, G., Horn, H., Ziepert, M., Pfreundschuh, M., and Linch, D.

Subjects
Male, Time Factors, diffuse large B-cell lymphoma, Kaplan-Meier Estimate, MYC, elderly, Drug Administration Schedule, Proto-Oncogene Proteins c-myc, Antibodies, Monoclonal, Murine-Derived, Risk Factors, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Humans, Precision Medicine, Cyclophosphamide, Aged, Aged, 80 and over, Gene Rearrangement, Manchester Cancer Research Centre, Patient Selection, ResearchInstitutes_Networks_Beacons/mcrc, Age Factors, Middle Aged, United Kingdom, Treatment Outcome, Proto-Oncogene Proteins c-bcl-2, Doxorubicin, Vincristine, R-CHOP, Multivariate Analysis, Proto-Oncogene Proteins c-bcl-6, double-hit lymphoma, Prednisone, Female, Lymphoma, Large B-Cell, Diffuse, Rituximab
Abstract

Background: There is an on-going debate whether 2- or 3-weekly administration of R-CHOP is the preferred first-line treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL). The UK NCRI R-CHOP14v21 randomized phase 3 trial did not demonstrate a difference in outcomes between R-CHOP-14 and R-CHOP-21 in newly diagnosed DLBCL patients aged 19-88 years, but data on elderly patients have not been reported in detail so far. Here, we provide a subgroup analysis of patients ≥60 years treated on the R-CHOP14v21 trial with extended follow-up.Patients and methods: Six hundred and four R-CHOP14v21 patients ≥60 years were included in this subgroup analysis, with a median follow-up of 77.7 months. To assess the impact of MYC rearrangements (MYC-R) and double-hit-lymphoma (DHL) on outcome in elderly patients, we performed a joint analysis of cases with available molecular data from the R-CHOP14v21 (N = 217) and RICOVER-60 (N = 204) trials.Results: Elderly DLBCL patients received high dose intensities with median total doses of ≥98% for all agents. Toxicities were similar in both arms with the exception of more grade ≥3 neutropenia (P Conclusions: Our data support equivalence of both R-CHOP application forms in elderly DLBCL patients. Elderly MYC-R and DHL patients have inferior prognosis and should be considered for alternative treatment approaches.Trial numbers: ISCRTN 16017947 (R-CHOP14v21); NCT00052936 (RICOVER-60).

Published
2017

38. Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials

Author

Maurer, M.J., primary, Habermann, T.M., additional, Shi, Q., additional, Schmitz, N., additional, Cunningham, D., additional, Pfreundschuh, M., additional, Seymour, J.F., additional, Jaeger, U., additional, Haioun, C., additional, Tilly, H., additional, Ghesquieres, H., additional, Merli, F., additional, Ziepert, M., additional, Herbrecht, R., additional, Flament, J., additional, Fu, T., additional, Flowers, C.R., additional, and Coiffier, B., additional

Published
2018
Full Text
View/download PDF

39. Radiotherapy to bulky disease PET-negative after immunochemotherapy can be spared in elderly DLBCL patients: results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL > 60 study of the DSHNHL

Author

Pfreundschuh, M., Christofyllakis, K., Altmann, B., Ziepert, M., Haenel, M., Viardot, A., Neubauer, A., Held, G., Truemper, L., Schmidt, C., Kanz, L., Hallek, M., Schmitz, N., Heintges, T., Koelbel, C., Schneider, G., Ruebe, C., Hellwig, D., Poeschel, V., Murawski, N., Pfreundschuh, M., Christofyllakis, K., Altmann, B., Ziepert, M., Haenel, M., Viardot, A., Neubauer, A., Held, G., Truemper, L., Schmidt, C., Kanz, L., Hallek, M., Schmitz, N., Heintges, T., Koelbel, C., Schneider, G., Ruebe, C., Hellwig, D., Poeschel, V., and Murawski, N.

Published
2017

40. Anti-infective prophylaxis with aciclovir and cotrimoxazole significantly reduces the rate of infections and therapy-associated deaths in elderly patients with DLBCL undergoing R-CHOP immunochemotherapy

Author

Murawski, N., Amam, J., Altmann, B., Ziepert, M., Haenel, M., Viardot, A., Neubauer, A., Held, G., Truemper, L., Schmidt, C., Kanz, L., Hallek, M., Schmitz, N., Heintges, T., Koelbel, C., Poeschel, V., Pfreundschuh, M., Murawski, N., Amam, J., Altmann, B., Ziepert, M., Haenel, M., Viardot, A., Neubauer, A., Held, G., Truemper, L., Schmidt, C., Kanz, L., Hallek, M., Schmitz, N., Heintges, T., Koelbel, C., Poeschel, V., and Pfreundschuh, M.

Published
2017

41. Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma

Author

Mansouri, L. Noerenberg, D. Young, E. Mylonas, E. Abdulla, M. Frick, M. Asmar, F. Ljungström, V. Schneider, M. Yoshida, K. Skaftason, A. Pandzic, T. Gonzalez, B. Tasidou, A. Waldhueter, N. Rivas-Delgado, A. Angelopoulou, M. Ziepert, M. Arends, C.M. Couronné, L. Lenze, D. Baldus, C.D. Bastard, C. Okosun, J. Fitzgibbon, J. Dörken, B. Drexler, H.G. Roos-Weil, D. Schmitt, C.A. Munch-Petersen, H.D. Zenz, T. Hansmann, M.-L. Strefford, J.C. Enblad, G. Bernard, O.A. Ralfkiaer, E. Erlanson, M. Korkolopoulou, P. Hultdin, M. Papadaki, T. Grønbæk, K. Lopez-Guillermo, A. Ogawa, S. Küppers, R. Stamatopoulos, K. Stavroyianni, N. Kanellis, G. Rosenwald, A. Campo, E. Amini, R.-M. Ott, G. Vassilakopoulos, T.P. Hummel, M. Rosenquist, R. Damm, F.

Subjects
hemic and lymphatic diseases
Abstract

We recently reported a truncating deletion in the NFKBIE gene, which encodes IκB, a negative feedback regulator of NF-κB, in clinically aggressive chronic lymphocytic leukemia (CLL). Because preliminary data indicate enrichment of NFKBIE aberrations in other lymphoid malignancies, we screened a large patient cohort (n 5 1460) diagnosed with different lymphoid neoplasms. While NFKBIE deletions were infrequent in follicular lymphoma, splenic marginal zone lymphoma, and T-cell acute lymphoblastic leukemia (

Published
2016

43. Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial

Author

Kühnl, A., primary, Cunningham, D., additional, Counsell, N., additional, Hawkes, E.A., additional, Qian, W., additional, Smith, P., additional, Chadwick, N., additional, Lawrie, A., additional, Mouncey, P., additional, Jack, A., additional, Pocock, C., additional, Ardeshna, K.M., additional, Radford, J., additional, McMillan, A., additional, Davies, J., additional, Turner, D., additional, Kruger, A., additional, Johnson, P.W., additional, Gambell, J., additional, Rosenwald, A., additional, Ott, G., additional, Horn, H., additional, Ziepert, M., additional, Pfreundschuh, M., additional, and Linch, D., additional

Published
2017
Full Text
View/download PDF

44. RADIOTHERAPY TO BULKY DISEASE PET-NEGATIVE AFTER IMMUNOCHEMOTHERAPY CAN BE SPARED IN ELDERLY DLBCL PATIENTS: RESULTS OF a PLANNED INTERIM ANALYSIS OF THE FIRST 187 PATIENTS WITH BULKY DISEASE TREATED IN THE OPTIMAL > 60 STUDY OF THE DSHNHL

Author

Pfreundschuh, M., primary, Christofyllakis, K., additional, Altmann, B., additional, Ziepert, M., additional, Haenel, M., additional, Viardot, A., additional, Neubauer, A., additional, Held, G., additional, Truemper, L., additional, Dreyling, M., additional, Kanz, L., additional, Hallek, M., additional, Schmitz, N., additional, Heintges, T., additional, Kölbel, C., additional, Buecker, A., additional, Ruebe, C., additional, Hellwig, D., additional, Berdel, C., additional, Poeschel, V., additional, and Murawski, N., additional

Published
2017
Full Text
View/download PDF

45. PROGNOSTIC FACTORS AND IMPACT OF ETOPOSIDE IN ADULTS WITH SYSTEMIC ALK-POSITIVE ANAPLASTIC LARGE-CELL LYMPHOMA: A POOLED ANALYSIS OF SIX STUDIES

Author

Sibon, D., primary, Nguyen, D., additional, Schmitz, N., additional, Suzuki, R., additional, Feldman, A.L., additional, Gressin, R., additional, Lamant, L., additional, Weisenburger, D., additional, Nakamura, S., additional, Ziepert, M., additional, Maurer, M.J., additional, Bast, M., additional, Armitage, J.O., additional, Vose, J.M., additional, Tilly, H., additional, Jais, J.P., additional, and Savage, K.J., additional

Published
2017
Full Text
View/download PDF

46. ANTI-INFECTIVE PROPHYLAXIS WITH ACICLOVIR AND COTRIMOXAZOLE SIGNIFICANTLY REDUCES THE RATE OF INFECTIONS AND THERAPY-ASSOCIATED DEATHS IN ELDERLY PATIENTS WITH DLBCL UNDERGOING R-CHOP IMMUNOCHEMOTHERAPY

Author

Murawski, N., primary, Amam, J., additional, Altmann, B., additional, Ziepert, M., additional, Haenel, M., additional, Viardot, A., additional, Neubauer, A., additional, Held, G., additional, Truemper, L., additional, Dreyling, M., additional, Kanz, L., additional, Hallek, M., additional, Schmitz, N., additional, Heintges, T., additional, Koelbel, C., additional, Poeschel, V., additional, and Pfreundschuh, M., additional

Published
2017
Full Text
View/download PDF

47. First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma PatientsTreated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy

Author

D'Amore, Francesco Annibale, Leppä, S, Gomes da Silva, M, Relander, T, Brown, Peter De Nully, Weidmann, E, Lauritzsen, GF, Pezzutto, A, Van Hoof, A, Van Gelder, M, Doorduijn, J, Wu, KL, Kluin-Nelemans, JC, Lugtenburg, PJ, Jankovska, M, Merup, M, Fagerli, U-M, Walewski, J, Hagberg, H, Mariz, JM, Hansen, PB, Nösslinger, T, Janssens, A, Brandefors, L, Demuynck, H, Schaafsma, MR, Christiansen, Ilse, Salek, D, Jyrkkiö, S, Prochazka, V, Zijlstra, J, Böhmer, L, Greil, R, Stevens, W, Fijnheer, R, van Marwijk, M, Grube, M, Trümper, L, Wulf, G, Altmann, B, Ziepert, M, Loeffler, M, Jantunen, E, Hopfinger, G, Van den Neste, E, and Toldbod, H

Published
2012

48. First interim safety analysis of a phase III randomized trial in a newly diagnosed systemic peripheral T-cell lymphoma trated with CHOP chemotherapy with or without alemtuzumab and consolidated by autologous hematopoietic stem cell transplant

Author

D'Amore, Francesco Annibale, Gomes da Silva, M, Leppa, S, Relander, T, Pezzutto, A, Lauritzsen, GF, Weidmann, E, Van Gelder, M, Merup, M, Hagberg, H, Fagerli, UM, Brown, Peter De Nully, Boye Hansen, P, Mariz, JM, Jankovska, M, Walewski, J, Doorduijn, J, van Hoof, A, Christiansen, Ilse, Jyrkkiö, S, Kluin-Nelemans, JC, van Marwijk Kooy, M, Fijnheer, R, Stevens, W, Zijlstra, J, Böhmer, L, Lugtenburg, PJ, Grube, M, Prochazka, V, Salek, D, Greil, R, Trümper, L, Wulf, G, Altmann, B, Ziepert, M, Loeffler, M, Jantunen, E, Hopfinger, G, Van den Neste, E, and Toldbod, H

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results